proxyvotesnow.com

Home › Companies › ESPERION THERAPEUTICS INC. › 2023-2024

ESPERION THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and ESPERION THERAPEUTICS INC.’s Form 8-K, filed May 28, 2024 (Item 5.07 on EDGAR). Page generated October 18, 2026.

  • 7Reported items
  • 110Asset managers
  • 360Fund votes
  • May 23, 2024Meeting date

Results at a glance

Meeting of May 23, 2024: 6 items on ESPERION THERAPEUTICS INC.’s Form 8-K, filed May 28, 2024: 6 without a stated outcome.

Material dissent

  • The Company's stockholders approved Proposal 2. 74% of votes cast Outcome not stated Under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ESPERION THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ESPERION THERAPEUTICS INC.

These tallies are ESPERION THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 28, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ESPERION THERAPEUTICS INC. — official shareholder meeting results, meeting held May 23, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Antonio M. Gotto Jr., M.D., D.Phil. 87,858,914---- 7,863,58044,073,687 92%Not verified—
Elect Director: Nicole Vitullo 90,961,988---- 4,760,50644,073,687 95%Not verified—
The Company's stockholders approved Proposal 2. 70,745,16424,537,427439,903 --44,073,687 74%Not verified—
The Company's stockholders approved Proposal 3. 136,839,6072,422,428534,146 ---- 98%Not verified—
The Company's stockholders approved Proposal 4. 88,126,9937,007,381588,120 --44,073,687 93%Not verified—
The Company's stockholders approved Proposal 5. 88,771,1866,425,073526,235 --44,073,687 93%Not verified—

Source: ESPERION THERAPEUTICS INC., Form 8-K, filed with the SEC on May 28, 2024 — read the filing on EDGAR.

How asset managers voted at the ESPERION THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 110 asset managers that disclosed a ESPERION THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ESPERION THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Elect Director: Antonio M. Gotto Jr., M.D., D.Phil.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 87,858,914WITHHELD: 7,863,580
Details: description as filed, official tally, votes by 18 asset managers

Description as filed by funds: Election of Class II Directors: Antonio M. Gotto Jr., M.D., D.Phil.

ESPERION THERAPEUTICS INC.’s own tally for this item (“Elect Director: Antonio M. Gotto Jr., M.D., D.Phil.”): 87,858,914 for, 7,863,580 withheld, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 18 asset managers below reported 14,469,987 for, 102,309 withheld.

FOR
FOR: 14,469,987WITHHOLD: 102,309
Largest asset managers voting on “Election of Class II Directors: Antonio M. Gotto Jr., M.D., D.Phil.” at ESPERION THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST6,356,9890 00For
Vanguard6,295,3870 00For
JPMorgan1,197,0720 00For
Fidelity242,8430 00For
Lincoln Financial108,9190 00For
BlackRock83,3170 00For
Brighthouse47,5410 00For
Charles Schwab44,4380 00For
Blackstone Alternative Investment Funds00 042,500Withhold
Russell Investments38,4990 00For
Principal Exchange-Traded Funds00 029,151Withhold
Voya25,7820 00For
Nationwide6040 016,927Withhold
Jacob Funds Inc.14,7250 00For
Equitable13,8710 00For
Victory Capital00 09,340Withhold
Invesco00 02,623Withhold
John Hancock00 01,768Withhold

2. Elect Director: Nicole Vitullo

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 90,961,988WITHHELD: 4,760,506
Details: description as filed, official tally, votes by 18 asset managers

Description as filed by funds: Election of Class II Directors: Nicole Vitullo

ESPERION THERAPEUTICS INC.’s own tally for this item (“Elect Director: Nicole Vitullo”): 90,961,988 for, 4,760,506 withheld, per its Form 8-K filed May 28, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 18 asset managers below reported 14,572,296 for.

FOR
FOR: 14,572,296
Largest asset managers voting on “Election of Class II Directors: Nicole Vitullo” at ESPERION THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST6,356,9890 00For
Vanguard6,295,3870 00For
JPMorgan1,197,0720 00For
Fidelity242,8430 00For
Lincoln Financial108,9190 00For
BlackRock83,3170 00For
Brighthouse47,5410 00For
Charles Schwab44,4380 00For
Blackstone Alternative Investment Funds42,5000 00For
Russell Investments38,4990 00For
Principal Exchange-Traded Funds29,1510 00For
Voya25,7820 00For
Nationwide17,5310 00For
Jacob Funds Inc.14,7250 00For
Equitable13,8710 00For
Victory Capital9,3400 00For
Invesco2,6230 00For
John Hancock1,7680 00For

3. To approve an amendment to the Esperion Therapeutics, Inc. 2020 Employee Stock Purchase Plan.

No official matchCOMPENSATION

Combines 2 wordings of this item as funds reported it.

100% of fund votes cast · no official result

FOR
Details: votes by 18 asset managers

The 18 asset managers below reported 14,572,296 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 14,572,296
Largest asset managers voting on “To approve an amendment to the Esperion Therapeutics, Inc. 2020 Employee Stock Purchase Plan.” at ESPERION THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST6,356,9890 00For
Vanguard6,295,3870 00For
JPMorgan1,197,0720 00For
Fidelity242,8430 00For
Lincoln Financial108,9190 00For
BlackRock83,3170 00For
Brighthouse47,5410 00For
Charles Schwab44,4380 00For
Blackstone Alternative Investment Funds42,5000 00For
Russell Investments38,4990 00For
Principal Exchange-Traded Funds29,1510 00For
Voya25,7820 00For
Nationwide17,5310 00For
Jacob Funds Inc.14,7250 00For
Equitable13,8710 00For
Victory Capital9,3400 00For
Invesco2,6230 00For
John Hancock1,7680 00For

4. To approve an amendment to the Esperion Therapeutics, Inc. 2022 Stock Option and Incentive Plan.

No official matchCOMPENSATION

Combines 2 wordings of this item as funds reported it.

100% of fund votes cast · no official result

FOR
Details: votes by 18 asset managers

The 18 asset managers below reported 14,572,296 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 14,572,296
Largest asset managers voting on “To approve an amendment to the Esperion Therapeutics, Inc. 2022 Stock Option and Incentive Plan.” at ESPERION THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST6,356,9890 00For
Vanguard6,295,3870 00For
JPMorgan1,197,0720 00For
Fidelity242,8430 00For
Lincoln Financial108,9190 00For
BlackRock83,3170 00For
Brighthouse47,5410 00For
Charles Schwab44,4380 00For
Blackstone Alternative Investment Funds42,5000 00For
Russell Investments38,4990 00For
Principal Exchange-Traded Funds29,1510 00For
Voya25,7820 00For
Nationwide17,5310 00For
Jacob Funds Inc.14,7250 00For
Equitable13,8710 00For
Victory Capital9,3400 00For
Invesco2,6230 00For
John Hancock1,7680 00For

5. To approve the non-binding advisory resolution on the compensation of our named executive officers.

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

76% Fund and manager reports combined; may count the same shares twice · no official result

FORAGAINST
Details: votes by 108 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 18 asset managers voting on “To approve the non-binding advisory resolution on the compensation of our named executive officers.” at ESPERION THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST6,356,9890 00For
Vanguard6,295,3870 00For
JPMorgan1,197,0720 00For
Fidelity242,8430 00For
Lincoln Financial108,9190 00For
BlackRock83,3170 00For
Brighthouse47,5410 00For
Charles Schwab44,4380 00For
Blackstone Alternative Investment Funds42,5000 00For
Russell Investments038,499 00Against
Principal Exchange-Traded Funds29,1510 00For
Voya25,7820 00For
Nationwide17,5310 00For
Jacob Funds Inc.13,2751,450 00Mixed
Equitable13,8710 00For
Victory Capital9,3400 00For
Invesco2,6230 00For
John Hancock1,7680 00For

Fund voting reports, all 18 managers: 14,532,347 for, 39,949 against.

Institutional-manager reports: 99 asset managers voting on “To approve the non-binding advisory resolution on the compensation of our named executive officers.” at ESPERION THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
ORBIMED ADVISORS LLC016,213,933 00Against
Woodline Partners LP10,810,4920 00For
WASATCH ADVISORS LP7,535,6270 00For
GREAT POINT PARTNERS LLC7,456,0000 00For
DE Shaw4,357,2700 00For
Citadel2,571,3740 00For
Two Sigma2,132,1720 00For
BlackRock1,980,687269 00For
Goldman Sachs1,600,2500 00For
PLATINUM INVESTMENT MANAGEMENT LTD1,597,5420 00For
MARSHALL WACE, LLP01,425,133 00Against
JACOBS LEVY EQUITY MANAGEMENT, INC741,9980 00For
Wellington0445,605 00Against
GEODE CAPITAL MANAGEMENT, LLC316,9610 00For
State Street303,6360 00For
Corient Private Wealth LLC239,0005,000 00For
NJ State Employees Deferred Compensation Plan195,1250 00For
BALYASNY ASSET MANAGEMENT L.P.0184,020 00Against
HighTower Advisors, LLC181,7510 00For
Northern Trust162,8230 00For
UBS142,4180 00For
JPMorgan114,3520 00For
PINNACLE ASSOCIATES LTD99,9580 00For
Point7268,7880 00For
STIFEL NICOLAUS & CO INC \MO\65,2250 00For

Institutional-manager reports, all 99 managers: 43,180,329 for, 18,423,039 against. Showing the 25 largest; see all in the interactive database.

6. Advisory Vote to Ratify Named Executive Officers' Compensation

No official matchSECTION 14A SAY-ON-PAY VOTES

100% of fund votes cast · no official result

FOR
Details: votes by 2 asset managers

The 2 asset managers below reported 1,335,654 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 1,335,654
Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at ESPERION THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
JPMorgan1,335,5950 00For
TD ASSET MANAGEMENT INC590 00For

7. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year…

No official matchAUDIT-RELATED

Combines 2 wordings of this item as funds reported it.

100% of fund votes cast · no official result

FOR
Details: description as filed, votes by 18 asset managers

Description as filed by funds: To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

The 18 asset managers below reported 14,572,296 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 14,572,296
Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fi” at ESPERION THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
WASATCH FUNDS TRUST6,356,9890 00For
Vanguard6,295,3870 00For
JPMorgan1,197,0720 00For
Fidelity242,8430 00For
Lincoln Financial108,9190 00For
BlackRock83,3170 00For
Brighthouse47,5410 00For
Charles Schwab44,4380 00For
Blackstone Alternative Investment Funds42,5000 00For
Russell Investments38,4990 00For
Principal Exchange-Traded Funds29,1510 00For
Voya25,7820 00For
Nationwide17,5310 00For
Jacob Funds Inc.14,7250 00For
Equitable13,8710 00For
Victory Capital9,3400 00For
Invesco2,6230 00For
John Hancock1,7680 00For

Largest ESPERION THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 189,460,293 shares outstanding at the time of that meeting.

Fund voting reports: top ESPERION THERAPEUTICS INC. shareholders by shares voted on “To approve the non-binding advisory resolution on the compensation of our named executive…”, 2023-2024
#Asset manager % of shares outstanding
1WASATCH FUNDS TRUST 3.36%
2Vanguard 3.32%
3JPMorgan 0.63%
4Fidelity 0.13%
5Lincoln Financial 0.06%
6BlackRock 0.04%
7Brighthouse 0.03%
8Charles Schwab 0.02%
9Blackstone Alternative Investment Funds 0.02%
10Russell Investments 0.02%
Institutional-manager reports: top ESPERION THERAPEUTICS INC. shareholders by shares voted on “To approve the non-binding advisory resolution on the compensation of our named executive…”, 2023-2024
#Asset manager % of shares outstanding
1ORBIMED ADVISORS LLC 8.56%
2Woodline Partners LP 5.71%
3WASATCH ADVISORS LP 3.98%
4GREAT POINT PARTNERS LLC 3.94%
5DE Shaw 2.30%
6Citadel 1.36%
7Two Sigma 1.13%
8BlackRock 1.05%
9Goldman Sachs 0.84%
10PLATINUM INVESTMENT MANAGEMENT LTD 0.84%

Reported ESPERION THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

ESPERION THERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season
Holder % outstanding Disclosure
BlackRock 7.83% 13F
Vanguard Group 6.38% 13F
BB Biotech AG 4.85% 13G
Millennium Management 3.00% 13F
D.E. Shaw 2.71% 13F
Morgan Stanley 2.14% 13F
Two Sigma 2.10% 13F
Citadel Advisors 1.98% 13F
Renaissance Technologies 1.12% 13F
Geode Capital 0.93% 13F

Percentages above are of 189,460,293 shares outstanding, as reported by ESPERION THERAPEUTICS INC. on its Form 10-Q dated May 1, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ESPERION THERAPEUTICS INC.’s 10-Q dated May 1, 2024. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At ESPERION THERAPEUTICS INC.'s shareholder meeting held May 23, 2024, in the 2023-2024 proxy season, 110 asset managers reported how they voted in their SEC Form N-PX filings, covering 360 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. ESPERION THERAPEUTICS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve the non-binding advisory resolution on the compensation of our named executive… — the reporting funds and managers cast 76% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.

ESPERION THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.